Quote Date:

Data delayed 15 minutes Currency in USD

Company Description

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Revenue $53,373$39,670$52,546$52,825$48,851
Cost of Revenue Expense $11,433$8,173$11,240$12,328$9,647
Gross Profit $41,940$31,497$41,306$40,497$39,204
Selling, General & Administrative Expense $14,999$10,448$14,784$14,838$14,808
Operating Income $14,255$11,861$14,106$13,730$12,978
Interest Expense $966$636$1,271$1,186$1,200
Pretax Income $13,785$12,831$12,305$8,351$8,964
Provision Tax Income -$10,066$1,270-$9,049$1,123$1,990
Net Income $23,821$11,547$21,308$7,215$6,960
EBITDA $20,379$17,521$19,845$15,294$15,321
Cash & Cash Equivalents $0$0$1,342$2,595$3,641
Short Term Receivables $0$0$8,221$8,225$8,176
Inventories $0$0$7,578$6,783$7,513
Total Cash $0$0$0$0$0
Current Assets $0$0$41,141$38,949$43,804
Total Assets $0$0$171,797$171,615$167,460
Short Term Debt $0$0$9,954$10,688$10,160
Accounts Payable $0$0$4,656$4,536$3,620
Total Current Liabilities $0$0$30,427$31,115$29,399
Long Term Debt $0$0$33,538$31,398$28,818
Deferred Tax Liabilities $0$0$3,900$30,753$26,877
Total Liabilities $0$0$100,141$111,775$102,462
Total Stock Holders Equity $0$0$71,308$59,544$64,720
Total Equity $0$0$71,308$59,544$64,720
Operating Cash Flow $0$0$0$0$0
Investing Cash Flow $3,414$8,193-$4,741-$7,811-$2,980
Dividends Paid $5,930$4,021$7,659$7,317$6,940
Financing Cash Flow -$16,013-$12,628-$13,035-$8,921-$10,233
Free Cash Flow $10,957$4,988$14,253$13,902$13,016

Unique Data Points

Alliances Revenue $3,634$2,819$2,927$1,746$1,313
Essential Revenue $22,204--$10,590$23,628$21,982
Premarian Revenue $871$605$977$1,016$1,018
Quarterly Dividend Payout -$2,032-$2,032$84,278$82,685-$6,940
Viagra Revenue $718$509$1,205$1,565$1,708
Emerging Markets Chantix/Champix Revenue $55$42$43$33$43
Emerging Markets Internal Medicine Revenue $705$539$591$494$479
Emerging Markets Lyrica IH Revenue $216$159$216$217$276
Emerging Markets PFIZER INNOVATIVE Revenue $4,837$3,582$4,381$3,724$4,020
Emerging Markets All Other Biosimilars Revenue $16$13$17$16$4
Emerging Markets All other Internal Medicine Revenue $141$109$122$211$136
Emerging Markets All other LEP Revenue $1,602$1,168$1,571$1,395$1,704
Emerging Markets All other Oncology Revenue $10$8$7$10$10
Emerging Markets All other Peri-LOE Products Revenue $67$47$70$72$88
Emerging Markets All other Rare Disease Revenue $66$50$62$23$8
Emerging Markets All other SIP Revenue $702$515$711$660$511
Emerging Markets All other Vaccines Revenue $52$46$32$19$5
Emerging Markets Alliance revenues Revenue $132$71$199$27$11
Emerging Markets Benefix Revenue $72$53$60$47$43
Emerging Markets Biosimilars Revenue $52$42$44$30$7
Emerging Markets Bosulif Revenue $8$6$5----
Emerging Markets Celebrex Revenue $300$63$311$303$350
Emerging Markets Consumer Healthcare Revenue $920$696$882$802$909
Emerging Markets Effexor Revenue $79$60$77$79$91
Emerging Markets Enbrel (Outside Canada) Revenue $600$425$647$632$790
Emerging Markets Fragmin Revenue $61$44$58$52$54
Emerging Markets FSME/IMMUN-TicoVac Revenue $21$19$17$18$16
Emerging Markets Genotropin Revenue $95$69$96$87$93
Emerging Markets Ibrance Revenue $207$158$144$43$4
Emerging Markets Inflammation & Immunology (I&I) Revenue $703$505$723$675$812
Emerging Markets Inflectra/Remsima Revenue $37$30$27$14$3
Emerging Markets Inlyta Revenue $58$44$44$43$33
Emerging Markets Legacy Established Products (LEP) Revenue $4,474$3,359$4,074$3,913$4,440
Emerging Markets Lipitor Revenue $1,529$1,167$1,285$1,157$1,236
Emerging Markets Lyrica EH Revenue $110$18$115$109$136
Emerging Markets Medrol Revenue $92$67$94$90$101
Emerging Markets Norvasc Revenue $719$558$616$622$616
Emerging Markets Oncology Revenue $714$544$613$440$398
Emerging Markets Peri-LOE Products Revenue $1,605$1,243$1,323$1,289$1,471
Emerging Markets Pfizer CentreOne Revenue $161$142$43$55$58
Emerging Markets PFIZER ESSENTIAL HEALTH Revenue $7,698$5,775$7,019$6,704$7,113
Emerging Markets Precedex Revenue $44$34$47----
Emerging Markets Premarin Family Revenue $26$18$27$29$33
Emerging Markets Prevnar/Prevenar 13 Revenue $1,365$970$1,195$1,011$1,139
Emerging Markets Pristiq Revenue $62$44$73$60$58
Emerging Markets Rare Disease Revenue $358$264$328$268$263
Emerging Markets Refacto AF/Xyntha Revenue $112$83$94$65$52
Emerging Markets Relpax Revenue $5$0$17$16$17
Emerging Markets Revatio Revenue $24$17$33$32$32
Emerging Markets Somavert Revenue $13$9$15$14$14
Emerging Markets Sterile Injectable Pharmaceuticals (SIP) Revenue $1,693$1,276$1,515$1,315$1,114
Emerging Markets Sulperazon Revenue $580$457$460$383$323
Emerging Markets Sutent Revenue $259$195$262$243$270
Emerging Markets Total Lyrica Revenue $312$220$331$326$411
Emerging Markets Total Viagra Revenue $305$230$300$294$313
Emerging Markets Toviaz Revenue $12$9$11$11$12
Emerging Markets Tygacil Revenue $142$73$131$119$124
Emerging Markets Vaccines Revenue $1,438$1,035$1,242$1,046$1,160
Emerging Markets Vfend Revenue $274$200$247$244$267
Emerging Markets Viagra EH Revenue $305$230$300$294$313
Emerging Markets Xalatan/Xalacom Revenue $107$78$104$110$122
Emerging Markets Xalkori Revenue $174$135$139$100$79
Emerging Markets Xanax/Xanax XR Revenue $54$35$73$69$75
Emerging Markets Xeljanz Revenue $102$79$75$43$22
Emerging Markets Zithromax/Zmax Revenue $194$150$175$164$168
Emerging Markets Zoloft Revenue $141$106$130$118$124
Emerging Markets Zyvox Revenue $180$131$174$177$228
Europe All Other Biosimilars Revenue $101$75$93$133$28
Europe All other I&I Revenue -$14-$9-$17-$9--
Europe All other Internal Medicine Revenue $8$8$4$55-$129
Europe All other LEP Revenue $1,092$832$917$855$815
Europe All other Oncology Revenue $1$12-$5$33$28
Europe All other Peri-LOE Products Revenue $84$51$75$85$141
Europe All other Rare Disease Revenue $121$90$109$63$57
Europe All other SIP Revenue $336$246$350$383$269
Europe All other Vaccines Revenue $185$136$158$157$91
Europe BeneFIX Revenue $165$119$192$243$263
Europe Biosimilars Revenue $415$309$355$277$55
Europe BMP2 Revenue $0$0$0----
Europe Bosulif Revenue $50$37$33----
Europe Celebrex Revenue $28$20$29$31$45
Europe CentreOne Revenue $143$114$110$160$182
Europe Chantix/Champix Revenue $83$60$78$78$80
Europe Consumer Healthcare Revenue $466$335$431$410$414
Europe Effexor Revenue $60$43$60$61$71
Europe Eliquis Alliance Revenue $887$692$630$379$224
Europe Enbrel Revenue $1,238$881$1,410$1,852$2,130
Europe Essential Health Revenue $3,256$2,340$3,360$4,014$4,443
Europe Fragmin Revenue $151$110$147$162$179
Europe FSME/IMMUN-TicoVac Revenue $124$111$117$100$78
Europe Genotropin Revenue $182$134$177$186$205
Europe Ibrance Revenue $360$483$122$21$1
Europe Inflammation & Immunology (I&I) Revenue $1,317$947$1,432$1,862$2,142
Europe Inflectra/Remsima Revenue $313$234$261$154$27
Europe Inlyta Revenue $53$37$70$103$109
Europe Innovative Revenue $5,601$4,317$5,149$5,314$5,271
Europe Internal Medicine Revenue $1,049$812$780$578$248
Europe Legacy Established Products (LEP) Revenue $1,539$1,108$1,500$1,562$1,633
Europe Lipitor Revenue $188$133$184$202$207
Europe Medrol Revenue $49$36$50$51$57
Europe Norvasc Revenue $68$50$66$68$75
Europe Oncology Revenue $954$930$720$649$633
Europe Peri-LOE Products Revenue $567$383$770$1,295$1,991
Europe Premarin family Revenue $2$1$4$4$8
Europe Prevnar/Prevenar 13 Revenue $646$418$644$626$655
Europe Pristiq Revenue $30$22$28$22$18
Europe Rare Disease Revenue $859$627$892$959$1,010
Europe Refacto AF/Xyntha Revenue ----------
Europe Relpax Revenue $9$0$33$37$62
Europe Revatio Revenue $42$27$68$119$128
Europe Somavert Revenue $131$97$125$122$121
Europe Sterile Injectable Pharmaceuticals (SIP) Revenue $616$449$626$665$568
Europe Sutent Revenue $324$240$323$338$366
Europe Total Alliance Revenue $842$660$593$382$250
Europe Total Lyrica Revenue $279$190$438$692$1,047
Europe Total Viagra Revenue $51$39$46$50$56
Europe Toviaz Revenue $71$52$67$65$72
Europe Tygacil Revenue $75$53$79$70$64
Europe Vaccines Revenue $957$666$894$854$824
Europe Vfend Revenue $41$28$56$191$254
Europe Xalatan/Xalacom Revenue $73$49$71$73$91
Europe Xalkori Revenue $165$121$175$154$129
Europe Xanax/Xanax XR Revenue $70$45$86$85$85
Europe Xeljanz Revenue $93$75$39$20$12
Europe Zithromax/Zmax Revenue $49$36$45$43$43
Europe Zoloft Revenue $40$30$36$34$33
Europe Zyvox Revenue $19$14$29$101$300
International All Other Biosimilars Revenue $118$88$112$110$33
International All other I&I Revenue $35$26$47$52$64
International All other Internal Medicine Revenue $185$142$165$375$98
International All other LEP Revenue $3,531$2,578$3,480$3,162$2,776
International All other Oncology Revenue $23$30$17$76$56
International All other Peri-LOE Products Revenue $221$146$218$234$326
International All other Rare Disease Revenue $249$185$228$126$91
International All other SIP Revenue $1,336$965$1,390$1,469$1,008
International All other Vaccines Revenue $254$194$205$182$98
International Benefix Revenue $324$236$350$410$428
International Biosimilars Revenue $488$368$413$315$63
International BMP2 Revenue $0$0$0----
International Bosulif Revenue $95$71$62----
International Celebrex Revenue $606$443$610$618$686
International CentreOne Revenue $294$242$169$240$278
International Chantix/Champix Revenue $259$188$256$245$245
International Consumer Healthcare Revenue $1,710$1,273$1,620$1,490$1,597
International Effexor Revenue $233$173$214$191$194
International Enbrel Revenue $2,222$1,588$2,452$2,908$3,332
International EpiPen Revenue $56$41$70$55$66
International Essential Health Revenue $13,965$10,239$13,558$14,066$14,836
International Fragmin Revenue $289$209$286$288$312
International FSME/IMMUN-TicoVac Revenue $145$130$136$102$95
International Genotropin Revenue $435$320$434$437$454
International Ibrance Revenue $746$807$301$68$4
International Inflammation & Immunology (I&I) Revenue $2,584$1,870$2,702$3,083$3,450
International Inflectra/Remsima Revenue $371$280$301$202$30
International Inlyta Revenue $190$138$213$239$225
International Innovative Revenue $14,038$10,572$12,962$12,424$12,311
International Internal Medicine Revenue $3,145$2,372$2,779$2,482$1,907
International Legacy Established Products (LEP) Revenue $7,883$5,772$7,554$7,435$8,170
International Lipitor Revenue $1,993$1,454$1,754$1,593$1,700
International Lyrica EH Revenue $376$251$554$801$1,184
International Lyrica IH Revenue $1,023$755$1,048$1,026$993
International Medicine Alliance Revenue $1,330$997$1,105$643$384
International Medrol Revenue $162$118$165$166$182
International Norvasc Revenue $977$745$888$923$956
International Oncology Revenue $2,155$1,868$1,671$1,396$1,295
International Peri-LOE Products Revenue $2,510$1,792$2,740$3,289$4,227
International Precedex Revenue $108$84$104----
International Premarin Family Revenue $51$36$56$60$67
International Prevnar/Prevenar 13 Revenue $2,247$1,494$2,268$2,074$2,220
International Pristiq Revenue $145$100$170$154$163
International Rare Disease Revenue $1,596$1,169$1,609$1,628$1,652
International Refacto AF/Xyntha Revenue $423$307$438$432$415
International Relpax Revenue $26$0$93$97$118
International Revatio Revenue $97$66$133$187$196
International Somavert Revenue $165$121$159$155$151
International Sterile Injectable Pharmaceuticals (SIP) Revenue $2,787$2,063$2,650$2,535$2,034
International Sulperazon Revenue $589$463$472$396$339
International Sutent Revenue $703$523$707$705$751
International Total Alliance revenues Revenue $1,185$920$890$631$424
International Total Lyrica Revenue $1,400$1,007$1,601$1,827$2,175
International Total Viagra Revenue $420$313$416$417$447
International Toviaz Revenue $183$135$173$160$151
International Tygacil Revenue $228$166$215$194$194
International Vaccines Revenue $2,847$2,019$2,580$2,342$2,412
International Vfend Revenue $399$287$407$558$643
International Viagra EH Revenue $410$313$381$383$410
International Viagra IH Revenue $10$0$35$34$36
International Xalatan/Xalacom Revenue $308$219$317$341$377
International Xalkori Revenue $398$299$371$310$256
International Xanax/Xanax XR Revenue $181$132$177$174$181
International Xeljanz Revenue $326$256$212$122$53
International Zithromax/Zmax Revenue $283$213$268$265$269
International Zoloft Revenue $247$182$238$243$316
International Zyvox Revenue $256$185$267$355$603
Rest of World Bosulif Revenue $38$29$26----
Rest of World Innovative Health Revenue $3,599$2,672$3,432$3,387$3,019
Rest of Wolrd Zithromax/Zmax Revenue $40$27$47$56$58
Rest of World All other I&I Revenue $49$35$55$61$64
Rest of World All other Internal Medicine Revenue $37$26$38$108$91
Rest of World All other LEP Revenue $972$712$993$912$918
Rest of World All other Oncology Revenue $12$10$14$33$18
Rest of World All other Peri-LOE Products Revenue $72$49$73$76$98
Rest of World All other Rare Disease Revenue $61$44$57$38$27
Rest of World All other SIP Revenue $342$248$330$426$227
Rest of World All other Vaccines Revenue $19$14$12$7$0
Rest of World Alliance Revenue $331$254$275$243$149
Rest of World BeneFIX Revenue $88$64$99$120$122
Rest of World Biosimilars Revenue $22$17$14$7$1
Rest of World Celebrex Revenue $269$197$270$283$291
Rest of World CentreOne Revenue $15$10$18$25$38
Rest of World Chantix/Champix Revenue $112$77$116$133$120
Rest of World Consumer Healthcare Revenue $326$243$309$278$274
Rest of World Effexor Revenue $93$70$76$52$30
Rest of World Enbrel Revenue $384$282$395$424$412
Rest of World EpiPen Revenue $56$41$70$55$66
Rest of World Essential Health Revenue $3,010$2,123$3,179$3,348$3,280
Rest of World Fragmin Revenue $76$54$80$74$80
Rest of World Genotropin Revenue $159$117$161$162$155
Rest of World Ibrance Revenue $178$166$34$4--
Rest of World Inflammation & Immunology (I&I) Revenue $565$419$547$546$497
Rest of World Inflectra/Remsima Revenue $20$16$13$6--
Rest of World Inlyta Revenue $79$57$84$99$83
Rest of World Internal Medicine Revenue $1,390$1,020$1,408$1,410$1,180
Rest of World Legacy Established Products (LEP) Revenue $1,870$1,305$1,979$1,958$2,099
Rest of World Lipitor Revenue $275$154$285$235$255
Rest of World Medrol Revenue $23$17$24$23$23
Rest of World Norvasc Revenue $189$136$206$235$263
Rest of World Peri-LOE Products Revenue $626$453$648$706$764
Rest of World Premarin family Revenue $24$17$27$28$27
Rest of World Prevnar/Prevenar 13 Revenue $434$304$431$435$425
Rest of World Pristiq Revenue $52$33$69$71$87
Rest of World Rare Disease Revenue $378$277$388$402$379
rest of World Refacto AF/Xyntha Revenue $51$37$53$52$44
Rest of World Relpax Revenue $12$0$42$45$40
Rest of World Revatio Revenue $30$22$31$36$35
Rest of World Somavert Revenue $19$14$19$17$16
Rest of World Sterile Injectable Pharmaceuticals (SIP) Revenue $478$338$508$555$352
Rest of World Sulperazon Revenue $10$7$12$15$16
Rest of World Sutent Revenue $121$89$121$122$117
Rest of World Total Alliance revenues Revenue $342$259$297$247$151
Rest of World Total Lyrica Revenue $808$596$832$809$718
Rest of World Total Viagra Revenue $71$52$69$72$76
Rest of World Toviaz Revenue $100$74$94$82$66
Rest of World Tygacil Revenue $5$4$7$7$7
Rest of World Vaccines Revenue $453$318$444$441$426
Rest of World Vfend Revenue $85$59$105$125$122
Rest of World Viagra EH Revenue $61$52$35$38$40
Rest of World Viagra IH Revenue $10$0$35$34$36
Rest of World Xalatan/Xalacom Revenue $128$92$141$159$164
Rest of World Xalkori Revenue $59$44$56$57$48
Rest of World Xanax/Xanax XR Revenue $17$12$17$20$21
Rest of World Xeljanz Revenue $131$101$98$59$19
Rest of World Zoloft Revenue $63$44$71$90$158
Rest of World Zyvox Revenue $58$41$65$78$92
Resto of World Oncology Revenue $489$396$337$308$265
Total Lyrica Revenue $4,903$3,649$5,064$4,966$4,839
United States All other Internal Medicine Revenue $122$82$146$177$133
United States All other LEP Revenue $1,368$1,020$1,596$1,650$1,419
United States All other Oncology Revenue $180$134$123$157$138
United States All other Peri-LOE Products Revenue $15$10$38$42$39
United States All other Rare Disease Revenue $66$48$72$43$17
United States All other SIP Revenue $1,926$1,435$2,448$3,042$1,556
United States All other Vaccines Revenue $41$32$88$84$18
United States Benefix Revenue $245$183$254$301$325
United States Biosimilars Revenue $234$190$118$4--
United States BMP2 Revenue $271$207$262$251$233
United States Celebrex Revenue $97$50$163$116$145
United States CentreOne Revenue $437$297$537$478$333
United States Chantix/Champix Revenue $866$666$743$597$426
United States Consumer Healthcare Revenue $1,870$1,358$1,851$1,918$1,798
United States Effexor Revenue $76$54$83$86$95
United States EpiPen Revenue $197$175$213$295$272
United States Essential Health Revenue $6,618$4,860$7,566$9,561$7,258
United States Eucrisa Revenue $139$105$67----
United States Fragmin Revenue $18$12$21$30$25
United States Genotropin Revenue $137$95$98$141$162
United States Ibrance Revenue $2,955$2,178$2,825$2,068$718
United States Inflammation & Immunology Revenue $1,470$1,080$1,265$845$468
United States Inflectra/Remsima Revenue $233$189$118$4--
United States Inlyta Revenue $119$88$125$161$205
United States Innovative Revenue $18,753$14,001$18,459$16,773$14,446
United States Internal Medicine Revenue $6,634$4,968$6,905$6,376$5,704
United States Legacy Established Products (LEP) Revenue $2,880$2,092$3,340$3,759$3,574
United States Lipitor Revenue $121$86$160$164$161
United States Medicine Alliance Revenue $1,936$1,559$1,418$966$872
United States Medrol Revenue $286$199$318$286$220
United States Norvasc Revenue $37$27$38$38$36
United States Oncology Revenue $4,644$3,426$4,384$3,166$1,659
United States Peri-LOE Products Revenue $523$417$483$930$1,099
United States Precedex Revenue $119$82$140----
United States Premarin family Revenue $819$568$921$957$951
United States Prevnar/Prevenar 13 Revenue $3,377$2,597$3,334$3,645$4,025
United States Pristiq Revenue $84$56$133$579$553
United States Rare Disease Revenue $659$483$632$740$774
United States Refacto AF/Xyntha Revenue $107$81$109$122$118
United States Relpax Revenue $17$0$143$226$233
United States Revatio Revenue $128$96$120$98$65
United States Somavert Revenue $102$74$95$77$68
United States Sterile Injectable Pharmaceuticals (SIP) Revenue $2,544$1,864$3,024$3,484$1,910
United States Sutent Revenue $358$262$374$390$367
United States Total Alliance Revenue $2,450$1,900$2,037$1,116$889
United States Total Lyrica Revenue $3,504$2,643$3,464$3,138$2,662
United States Total Viagra Revenue $297$195$790$1,148$1,261
United States Toviaz Revenue $143$121$85$99$116
United States Tygacil Revenue $26$20$45$81$110
United States Vaccines Revenue $3,477$2,688$3,422$3,729$4,043
United States Vfend Revenue $10$7$14$32$39
United States Xalatan/Xalacom Revenue $19$14$15$18$22
United States Xalkori Revenue $171$118$222$251$231
United States Xanax/Xanax XR Revenue $42$31$47$49$45
United States Xeljanz Revenue $1,304$964$1,133$805$471
United States Xtandi alliance Revenue $678$510$590$139--
United States Zithromax/Zmax Revenue $16$18$3$7$6
United States Zoloft Revenue $54$43$52$61$58
United States Zyvox Revenue -$9$0$15$67$263
Untied States All other I&I Revenue $27$11$66$40-$2
Worldwide All Other Biosimilars Revenue $119$89$112$126$33
Worldwide All other I&I Revenue $62$37$103$92$62
Worldwide All other Internal Medicine Revenue $308$224$312$517$232
Worldwide All other LEP Revenue $4,901$3,599$5,077$4,812$4,857
Worldwide All other Oncology Revenue $204$165$140$233$195
Worldwide All other Peri-LOE Products Revenue $238$157$257$275$362
Worldwide All other Rare Disease Revenue $313$231$300$167$108
Worldwide All other SIP Revenue $3,261$2,399$3,838$4,511$2,563
Worldwide All other Vaccines Revenue $296$227$293$266$114
Worldwide Benefix Revenue $570$420$603$713$751
Worldwide Biosimilars Revenue $723$558$532$318$63
Worldwide BMP2 Revenue $271$207$262$251$233
Worldwide Bosulif Revenue $225$155$186----
Worldwide Celebrex Revenue $704$494$775$732$831
Worldwide CentreOne Revenue $731$539$706$718$612
Worldwide Chantix/Champix Revenue $1,060$789$1,027$842$670
Worldwide Consumer Healthcare Revenue $3,580$2,630$3,473$3,407$3,395
Worldwide Effexor Revenue $310$228$297$277$287
Worldwide Enbrel Revenue $2,222$1,588$2,452$2,908$3,332
Worldwide EpiPen Revenue $252$215$290$387$339
Worldwide Essential Health Revenue $20,580$15,096$21,124$23,628$22,093
Worldwide Eucrisa Revenue $139$105$67----
Worldwide Fragmin Revenue $305$220$306$319$335
Worldwide FSME/IMMUN-TicoVac Revenue $145$130$136$115$95
Worldwide Genotropin Revenue $572$415$532$578$616
Worldwide Ibrance Revenue $3,701$2,985$3,126$2,136$723
Worldwide Inflammation & Immunology Revenue $4,055$2,951$3,967$3,928$3,917
Worldwide Inflectra/Remsima Revenue $604$469$419$192$30
Worldwide Inlyta Revenue $309$226$340$401$430
Worldwide Innovative Revenue $32,791$24,573$31,422$29,196$26,757
Worldwide Internal Medicine Revenue $9,780$7,340$9,684$8,858$7,610
Worldwide Legacy Established Products (LEP) Revenue $10,763$7,864$10,893$11,193$11,745
Worldwide Lipitor Revenue $2,113$1,539$1,914$1,758$1,860
Worldwide Lyrica EH Revenue $376$251$554$801$1,184
Worldwide Lyrica IH Revenue $4,527$3,397$4,512$4,165$3,655
Worldwide Medicine Alliance Revenue $3,341$2,631$2,523$1,609$1,257
Worldwide Medrol Revenue $450$319$483$449$402
Worldwide Norvasc Revenue $1,013$772$926$962$992
Worldwide Oncology Revenue $6,799$5,294$6,057$4,563$2,955
Worldwide Peri-LOE Products Revenue $3,033$2,208$3,223$4,220$5,326
Worldwide Precedex Revenue $227$166$243$259--
Worldwide Prevnar/Prevenar 13 Revenue $5,823$4,290$5,601$5,719$6,247
Worldwide Pristiq Revenue $229$156$304$731$716
Worldwide Rare Disease Revenue $2,254$1,651$2,241$2,369$2,426
Worldwide Refacto AF/Xyntha Revenue $430$288$551$554$533
Worldwide Replax Revenue $43$0$235$323$351
Worldwide Revatio Revenue $225$163$252$285$260
Worldwide Somavert Revenue $266$195$253$232$218
Worldwide Sterile Injectable Pharmaceuticals (SIP) Revenue $5,332$3,928$5,673$6,018$3,945
Worldwide Sulperazon Revenue $589$463$472$396$339
Worldwide Sutent Revenue $1,061$785$1,081$1,095$1,120
Worldwide Toviaz Revenue $267$197$257$258$266
Worldwide Tygacil Revenue $255$186$260$275$305
Worldwide Vaccines Revenue $6,325$4,708$6,001$6,071$6,454
Worldwide Vfend Revenue $410$295$420$590$681
Worldwide Viagra EH Revenue $606$509$381$383$410
Worldwide Viagra IH Revenue $112$0$822$1,181$1,297
Worldwide Xalatan/Xalacom Revenue $327$233$335$364$399
Worldwide Xalkori Revenue $569$417$595$561$487
Worldwide Xanax Revenue $240$180$225$221$223
Worldwide Xeljanz Revenue $1,631$1,221$1,344$927$523
Worldwide Xtandi alliance Revenue $678$510$590$139--
Worldwide Zithromax/Zmax Revenue $284$216$270$272$276
Worldwide Zoloft Revenue $299$223$291$304$374
Worldwide Zyvox Revenue $245$184$281$421$882